Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Disposition and Nephrotoxicity
NCT03817970Phase 3Active, not recruiting
- Sponsor
- University of Colorado Denver
- Start
- Nov 2019
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Nausea and Vomiting comparing Granisetron, Ondansetron and Palonosetron (3 arms). Primary endpoints: Kidney Injury Assessed by Biomarker Panel at 3 days and Effects of 5-HT3 Antagonist Antiemetic Drugs on Cisplatin Secretion at 3 days. Started Nov 2019; status: active, not recruiting.
02
Drugs
granisetronondansetronpalonosetron
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT03817970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817970.